CATALOGO DEI PRODOTTI DELLA RICERCA

Bria, Emilio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.763
EU - Europa 4.980
AS - Asia 2.160
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 11
OC - Oceania 8
AF - Africa 4
Totale 12.941
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.750
CN - Cina 2.070
GB - Regno Unito 2.042
FR - Francia 561
IE - Irlanda 482
SE - Svezia 471
IT - Italia 451
FI - Finlandia 422
DE - Germania 353
UA - Ucraina 88
BE - Belgio 30
IN - India 22
NL - Olanda 20
CH - Svizzera 19
TR - Turchia 17
RU - Federazione Russa 16
IR - Iran 15
EU - Europa 14
CA - Canada 11
JP - Giappone 7
AU - Australia 6
CL - Cile 6
VN - Vietnam 6
PH - Filippine 5
PL - Polonia 5
HK - Hong Kong 4
AZ - Azerbaigian 3
BG - Bulgaria 3
CZ - Repubblica Ceca 3
MK - Macedonia 3
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CM - Camerun 2
EG - Egitto 2
ES - Italia 2
LU - Lussemburgo 2
LV - Lettonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
SA - Arabia Saudita 2
SG - Singapore 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
BR - Brasile 1
CO - Colombia 1
CR - Costa Rica 1
EC - Ecuador 1
EE - Estonia 1
IL - Israele 1
MX - Messico 1
RO - Romania 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 12.941
Salva come PNG Salva come JPEG
Città #
Southend 1.919
Chandler 1.091
Woodbridge 966
Ann Arbor 620
Dublin 482
Jacksonville 444
Houston 402
Beijing 385
Jinan 246
Lawrence 237
Princeton 237
Ashburn 232
Wilmington 191
Nanjing 187
Shenyang 156
Hebei 121
New York 99
Tianjin 93
Verona 86
Ningbo 75
Changsha 74
Haikou 70
Helsinki 64
Hangzhou 57
Nanchang 57
Milan 54
Sindelfingen 54
Zhengzhou 54
Jiaxing 48
Taizhou 48
Guangzhou 44
Taiyuan 37
Seattle 33
Brussels 30
Fuzhou 26
Lanzhou 26
Norwalk 25
Falls Church 24
Redwood City 24
Dearborn 22
Lancaster 22
Rome 16
Boardman 15
Bologna 15
Chicago 13
Fairfield 13
Redmond 13
Augusta 12
Düsseldorf 11
Washington 11
Zurich 11
Detroit 9
Los Angeles 9
San Francisco 9
Clearwater 8
Kochi 7
Trento 7
Zanjan 7
Auburn Hills 6
Mountain View 6
San Mateo 6
Isola della Scala 5
Markgröningen 5
Ardabil 4
Brescia 4
Brugnera 4
Bussolengo 4
Duncan 4
Fremont 4
Groningen 4
Kemerovo 4
Lille 4
Monmouth Junction 4
Padova 4
Renton 4
Riva 4
San Diego 4
Tappahannock 4
Toronto 4
Trieste 4
Xiangfen 4
Amsterdam 3
Baku 3
Cambridge 3
Chaoyang 3
Florence 3
Genoa 3
Henderson 3
Leawood 3
Melbourne 3
Montréal 3
Mumbai 3
Novokuznetsk 3
Phoenix 3
Puxian 3
Qingdao 3
Sant'Ambrogio di Valpolicella 3
Yicheng 3
Alexandria 2
Austin 2
Totale 9.503
Salva come PNG Salva come JPEG
Nome #
Le linee guida AIOM, ASCO e MASCC-ESMO sull'emesi da chemioterapia e radioterapia: considerazioni e approfondimenti. 155
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 143
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 127
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 125
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 116
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 114
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 113
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 111
Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis 106
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 100
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 99
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 99
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 99
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 98
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 97
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 97
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 97
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 96
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 94
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 94
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 93
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 93
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 93
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 93
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 92
Adenocarcinoma of the paraurethral glands: a case report 90
Correction: The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 90
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 89
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 87
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 86
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 86
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 85
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer 84
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 84
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 82
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 81
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 76
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 76
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients 75
Clinical meta-analyses of targeted therapies in adenocarcinoma. 74
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 74
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 74
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 71
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 71
The development of PARP as a successful target for cancer therapy 71
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 71
Clinical meta-analyses of targeted therapies in adenocarcinoma. 70
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 70
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 69
Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology 69
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 68
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 68
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 67
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 67
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 67
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 67
Terapia cronomodulata 66
Comparision of CEA, MCA, CA 15-3 and CA 27-29 in Follow-Up and Monitoring Therapeutic Response in Breast Cancer Patients 66
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 66
Skin Testing and Hypersensitivity Reactions to Oxaliplatin 65
Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges 64
Antiblastic Chemotherapy in the presence of Abdominal Aorta Aneurysm (AAA): guidelines 63
Metastatic breast cancer: is global survival increase a realistic endpoint in phase III clinical trials? Studies on taxanes; studies on trastuzumab 63
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 63
Molecular Typing of Lung Adenocarcinoma on Cytological Samples in the Next-Generation Sequencing Era 63
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma 62
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 62
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 62
Chemotherapy in metastatic renal cell carcinoma today? A systematic review. 61
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 61
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 61
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 61
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 61
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers 61
Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment 61
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 61
eComment. Does resected lymph-node number influence survival in non-small cell lung cancer? 60
2-weekly docetaxel: issues for clinical practice. 60
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 60
Do immune checkpoint inhibitors need new studies methodology? 60
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 59
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 58
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 58
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 58
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 58
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 57
Contralateral Solitary Testis Metastasis Antedating Renal Cell Carcinoma: A Case-Report and Review 57
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 57
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 57
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 57
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 56
Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer 56
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 56
Sorafenib for lung cancer: is the "Battle" still open ? 55
Contrast-enhanced Computed Tomographic Colonography in the Follow-up of Colorectal Cancer Patients: A Feasibility Study 55
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 54
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 54
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 54
The obesity paradox in cancer: clinical insights and perspectives 53
Acute emesis: Moderately emetogenic chemotherapy. 52
Totale 7.617
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.806
article - articoli 40.993
book - libri 306
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.507
Totale 87.612
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019173 0 0 0 0 0 0 0 0 0 16 38 119
2019/20201.334 264 22 21 58 128 134 171 54 115 89 76 202
2020/20211.535 155 529 56 190 221 137 22 14 15 19 154 23
2021/20221.670 106 546 11 160 43 30 27 99 67 41 137 403
2022/20233.136 272 268 319 588 276 755 33 192 292 19 88 34
2023/20241.196 78 115 118 155 221 226 41 191 32 19 0 0
Totale 13.173